Michael Gelband’s Pfizer PFE Stock Holding History

Michael Gelband’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,300	Closed	-$61K	–	1876
2024 Q4	$61K	Buy	+2,300	New	+$62.4K	﹤0.01%	1419
2024 Q3	–	Sell	-110,700	Closed	-$3.1M	–	1983
2024 Q2	$3.1M	Buy	+110,700	New	+$3.05M	0.02%	611

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Michael Gelband's PFE Position: Q2 2026 in Review

Michael Gelband sold out of Pfizer (PFE) in Q2 2026, closing a stake of 816,068 shares — an estimated $22.9M sold.

Michael Gelband first reported a position in PFE in Q1 2019 and held it in 21 quarters. The position peaked at $47.6M in Q1 2025. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Michael Gelband reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 816,068 Pfizer shares in Q2 2026, an estimated $22.9M.
Michael Gelband first reported a position in Pfizer in Q1 2019 and held it in 21 quarters.
Michael Gelband's Pfizer position peaked at $47.6M in Q1 2025.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.